Our work supports the notion that human Hi-FGF-2 in the heart is a clinically relevant target, and that strategies aimed at reducing endogenous Hi-FGF-2 production or activity should be considered to prevent maladaptive remodelling associated with heart disease. Here, FGF2 is linked to heart disorder.